thanks for the post - i think studies like this are exactly the reason why rprx and androxal were met with resistance by the FDA on a T only endpoint. ironically, its also data such as this that opens the door for possible success in metabolic syndrome
1. I'd have to go back and read the original article, but testosterone is poorly absorbed orally, even if micronized. sounds like the dose used was very small
2. there was a trend towards improved anthropomorphic measures with increased muscle mass and lower body fat despite the low dose/short duration of the study
3. there was an improvement in insulin sensitivity
4. the article was vague but i think what they intended to say was men on T collectively at the end of study had half the rate of metabolic syndrome
5. the above benefits were largely offset on biochemical parameters by worsening of the cholesterol profile. androxal didn't seem to show this effect, and in fact may have shown some improvement in cholesterol profile, but this will be something to be closely watched in the forthcoming trial and represents a real risk.
5. the key again is that much of the study was comprised of men with modestly low T, and no significant clinical pathology otherwise. examining a population with more severe T deprivation, and clear metabolic syndrome as defined by rigorous standards, may yet show a very different efficacy signal
